Sumitomo Pharma Co (TSE:4506) EPS (Basic): 円268.99 (TTM As of Mar. 2026)


TSE:4506 Sumitomo Pharma Co Ltd TSE:4506
55 GF Score
Price 円1,493.50
GF Value 円827.37
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Sumitomo Pharma Co EPS (Basic)?

Sumitomo Pharma Co TSE:4506 +3.57% 55 EPS (Basic) is 円268.99 as of Mar. 2026. GuruFocus rates TSE:4506 with a GF Score™ of 55/100 and a GF Value™ of 円827.37 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Sumitomo Pharma Co's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was 円-2.04. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was 円268.99.

Sumitomo Pharma Co's EPS (Diluted) for the three months ended in Mar. 2026 was 円-2.04. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was 円268.99.

Sumitomo Pharma Co's EPS without NRI for the three months ended in Mar. 2026 was 円-2.04. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was 268.99.

During the past 12 months, Sumitomo Pharma Co's average EPS without NRIGrowth Rate was 352.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Sumitomo Pharma Co's highest 3-Year average EPS without NRI Growth Rate was 95.60% per year. The lowest was -41.80% per year. And the median was 8.90% per year.

Sumitomo Pharma Co  (TSE:4506) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Sumitomo Pharma Co EPS (Basic) Related Terms

Sumitomo Pharma Co EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Sumitomo Pharma Co's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sumitomo Pharma Co EPS (Basic) Chart

Sumitomo Pharma Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 141.99 -187.55 -792.79 59.49 268.99

Sumitomo Pharma Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.08 28.21 220.63 22.19 -2.04
TSE:4506
55GF Score
Sumitomo Pharma Co Ltd TSE:4506
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sumitomo Pharma Co EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Sumitomo Pharma Co's Basic EPS for the fiscal year that ended in Mar. 2026 is calculated as

Basic EPS (A: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(106865-0)/397.289
=268.99

Sumitomo Pharma Co's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-812-0)/397.289
=-2.04

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円268.99

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of 円268.99 mean?
Sumitomo Pharma Co (TSE:4506) has a EPS (Basic) of 円268.99 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Sumitomo Pharma Co and its competitors.
Is Sumitomo Pharma Co's EPS (Basic) too high?
Sumitomo Pharma Co's current EPS (Basic) is 円268.99. Overall, Sumitomo Pharma Co has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sumitomo Pharma Co's EPS (Basic) compare to ZTS?
Sumitomo Pharma Co's EPS (Basic) of 円268.99 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Drug Manufacturers company?
A good EPS (Basic) depends on the Drug Manufacturers industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Sumitomo Pharma Co and its competitors. Sumitomo Pharma Co's current EPS (Basic) is 円268.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sumitomo Pharma Co stock overvalued right now?
Based on GuruFocus' analysis, Sumitomo Pharma Co (TSE:4506) is currently considered Significantly Overvalued. The stock's GF Value™ is 円827.37, compared to a current price of 円1,493.50 — trading 80.5% above its estimated fair value. The current EPS (Basic) is 円268.99. Sumitomo Pharma Co's overall GF Score™ is 55/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Sumitomo Pharma Co (TSE:4506), the current EPS (Basic) is 円268.99 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sumitomo Pharma Co (TSE:4506) Overvalued in 2026?

Based on GuruFocus' analysis, Sumitomo Pharma Co stock appears to be overvalued. The current stock price of 円1,493.50 is trading 80.5% above its estimated GF Value™ of 円827.37. GuruFocus considers Sumitomo Pharma Co to be Significantly Overvalued.

Key valuation signals for TSE:4506:

  • EPS (Basic): 円268.99
  • GF Value™: 円827.37 vs. price of 円1,493.50 (80.5% above fair value)
  • GF Score™: 55/100 with 6 warning signs

No single metric tells the full story. See the TSE:4506 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sumitomo Pharma Co Business Description

Address 6-8, Doshomachi 2-chome, Chuo-ku, Osaka, JPN, 541-0045
Sumitomo Pharma Co Ltd is a specialty and generic drug manufacturing company. Sumitomo's vast majority of sales are generated in North America, followed by Japan. The company's core business is its pharmaceutical products business. The pharmaceutical business maintains a focus on a variety of areas, including cardiovascular/diabetes, psychiatry & neurology, and specialty areas. Sumitomo considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
55GF Score

Get the complete analysis for TSE:4506

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円1,493.50
Price
円827.37
GF Value